Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsRichard A. Morgan, Steven A. Rosenberg, Cary Hsu
Estimating the term…
The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing at least one recombinant polynucleotide encoding the cytokine, wherein the polynucleotide comprises a non-native coding sequence encoding the cytokine. Also provided is the use of such compositions and T lymphocytes, or populations thereof, for the treatment or prevention of a medical condition e.g., cancer. A method of preparing the a T lymphocyte with enhanced T cell survival is further provided herein.
An isolated T lymphocyte expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response, wherein the recombinant polynucleotide comprises a non-native coding sequence encoding the cytokine and wherein the recombinant polynucleotide comprises SEQ ID NO:
A pharmaceutical composition comprising a T lymphocyte, or a population of T lymphocytes, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response, wherein the recombinant polynucleotide comprises a codon-optimized coding sequence encoding the cytokine and wherein the recombinant polynucleotide comprises SEQ ID NO:
A composition comprising T lymphocytes transformed with and expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of the immune response, wherein the recombinant polynucleotide comprises a codon-optimized coding sequence encoding the cytokine and wherein the recombinant polynucleotide comprises SEQ ID NO:
An isolated peripheral blood mononuclear cell (PBMC) expressing at least one recombinant polynucleotide encoding a cytokine that enhances PBMC survival during the contraction phase of an immune response, wherein the recombinant polynucleotide comprises a non-native coding sequence encoding the cytokine and wherein the recombinant polynucleotide comprises SEQ ID NO:
Dependencies are inferred from the claim text.